<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39350850</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>COVID-19 and Carcinogenesis: Exploring the Hidden Links.</ArticleTitle><Pagination><StartPage>e68303</StartPage><MedlinePgn>e68303</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e68303</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.68303</ELocationID><Abstract><AbstractText>The COVID-19 pandemic caused by the SARS-CoV-2 virus has been studied predominantly in terms of its immediate respiratory and systemic effects. However, emerging evidence suggests possible long-term effects, including its role in carcinogenesis. This comprehensive review explores the complex relationship between COVID-19 and cancer development, focusing on immune dysregulation, chronic inflammation, genetic and epigenetic alterations, and the impact of therapeutic interventions. We also focused on the molecular mechanisms by which SARS-CoV-2 may facilitate cancer progression, including the roles of angiotensin-converting enzyme 2 (ACE2), transmembrane serine protease 2 (TMPRSS2), and FURIN. Additionally, we examined the possible carcinogenic effects of long-term COVID-19 treatments and the interaction between co-infections and cancer risk. Our findings highlight the need for increased cancer surveillance in COVID-19 survivors. In the post-COVID-19 period, it can be thought that inflammation associated with excessive cytokine release, especially interleukin-6, genetic and epigenetic changes, and co-infections with oncogenic viruses such as Epstein-Barr virus or human papillomavirus may be effective in the development and progression of cancer. Further research is needed to explain the mechanisms underlying this relationship.</AbstractText><CopyrightInformation>Copyright © 2024, Tanrıverdi et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tanrıverdi</LastName><ForeName>Özgür</ForeName><Initials>Ö</Initials><AffiliationInfo><Affiliation>Medical Oncology, Muğla Sıtkı Koçman University Faculty of Medicine, Muğla, TUR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alkan</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Oncology, Muğla Sıtkı Koçman University Faculty of Medicine, Muğla, TUR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karaoglu</LastName><ForeName>Turan</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Primary Health Care, Bodrum State Hospital, Muğla, TUR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitaplı</LastName><ForeName>Sait</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Oncology, Muğla Sıtkı Koçman University Faculty of Medicine, Muğla, TUR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yildiz</LastName><ForeName>Aysegul</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Molecular Biology and Genetics, Muğla Sıtkı Koçman University Faculty of Medicine, Muğla, TUR.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cancer cell biology</Keyword><Keyword MajorTopicYN="N">cancer epidemiology</Keyword><Keyword MajorTopicYN="N">carcinogenesis</Keyword><Keyword MajorTopicYN="N">covid-19 outbreak</Keyword><Keyword MajorTopicYN="N">epigenetic changes</Keyword><Keyword MajorTopicYN="N">inflammatory cytokines</Keyword></KeywordList><CoiStatement>Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>4</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39350850</ArticleId><ArticleId IdType="pmc">PMC11441415</ArticleId><ArticleId IdType="doi">10.7759/cureus.68303</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>The 2019-new coronavirus epidemic: evidence for virus evolution. Benvenuto D, Giovanetti M, Ciccozzi A, Spoto S, Angeletti S, Ciccozzi M. J Med Virol. 2020;92:455–459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7166400</ArticleId><ArticleId IdType="pubmed">31994738</ArticleId></ArticleIdList></Reference><Reference><Citation>A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Chan JF, Yuan S, Kok KH, et al. Lancet. 2020;395:514–523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159286</ArticleId><ArticleId IdType="pubmed">31986261</ArticleId></ArticleIdList></Reference><Reference><Citation>Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. Rothe C, Schunk M, Sothmann P, et al. N Engl J Med. 2020;382:970–971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7120970</ArticleId><ArticleId IdType="pubmed">32003551</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Sungnak W, Huang N, Bécavin C, et al. Nat Med. 2020;26:681–687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8637938</ArticleId><ArticleId IdType="pubmed">32327758</ArticleId></ArticleIdList></Reference><Reference><Citation>Possible cancer-causing capacity of COVID-19: is SARS-CoV-2 an oncogenic agent? Jahankhani K, Ahangari F, Adcock IM, Mortaz E. Biochimie. 2023;213:130–138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10202899</ArticleId><ArticleId IdType="pubmed">37230238</ArticleId></ArticleIdList></Reference><Reference><Citation>The interplay between inflammatory pathways and COVID-19: a critical review on pathogenesis and therapeutic options. Choudhary S, Sharma K, Silakari O. Microb Pathog. 2021;150:104673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7709793</ArticleId><ArticleId IdType="pubmed">33278517</ArticleId></ArticleIdList></Reference><Reference><Citation>The intersection of COVID-19 and cancer: signaling pathways and treatment implications. Zong Z, Wei Y, Ren J, Zhang L, Zhou F. Mol Cancer. 2021;20:76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8126512</ArticleId><ArticleId IdType="pubmed">34001144</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 and the possible connection to ERs, ACE2, and RAGE: focus on susceptibility factors. Stilhano RS, Costa AJ, Nishino MS, et al. FASEB J. 2020;34:14103–14119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537138</ArticleId><ArticleId IdType="pubmed">32965736</ArticleId></ArticleIdList></Reference><Reference><Citation>Inflammation and tumor progression: signaling pathways and targeted intervention. Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, Li Y. Signal Transduct Target Ther. 2021;6:263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8273155</ArticleId><ArticleId IdType="pubmed">34248142</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyperinflammatory immune response and COVID- 19: a double-edged sword. Tan LY, Komarasamy TV, Rmt Balasubramaniam V. Front Immunol. 2021;12:742941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515020</ArticleId><ArticleId IdType="pubmed">34659238</ArticleId></ArticleIdList></Reference><Reference><Citation>Increased interleukin-6 is associated with long COVID-19: a systematic review and meta-analysis. Yin JX, Agbana YL, Sun ZS, et al. Infect Dis Poverty. 2023;12:43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10123579</ArticleId><ArticleId IdType="pubmed">37095536</ArticleId></ArticleIdList></Reference><Reference><Citation>Age-related influence on DNA damage, proteomic inflammatory markers and oxidative stress in hospitalized COVID-19 patients compared to healthy controls. Draxler A, Blaschke A, Binar J, et al. Redox Biol. 2023;67:102914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10585323</ArticleId><ArticleId IdType="pubmed">37832397</ArticleId></ArticleIdList></Reference><Reference><Citation>Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. García-Suárez J, de la Cruz J, Cedillo Á, et al. J Hematol Oncol. 2020;13:133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7542567</ArticleId><ArticleId IdType="pubmed">33032660</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19: consider cytokine storm syndromes and immunosuppression. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. Lancet. 2020;395:1033–1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system. Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. Cytokine Growth Factor Rev. 2020;53:25–32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7211650</ArticleId><ArticleId IdType="pubmed">32446778</ArticleId></ArticleIdList></Reference><Reference><Citation>Do the oxidative stress biomarkers predict COVID-19 outcome? An in-hospital cohort study. Neves FF, Pott-Junior H, Yamashita KM, et al. Free Radic Biol Med. 2023;207:194–199.</Citation><ArticleIdList><ArticleId IdType="pubmed">37454917</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical efficacy of probiotics in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. Wu JY, Huang PY, Liu TH, Kuo CY, Tsai YW, Tang HJ, Lai CC. Expert Rev Anti Infect Ther. 2023;21:667–674.</Citation><ArticleIdList><ArticleId IdType="pubmed">36881729</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer occurrence as the upcoming complications of COVID-19. Rahimmanesh I, Shariati L, Dana N, Esmaeili Y, Vaseghi G, Haghjooy Javanmard S. Front Mol Biosci. 2021;8:813175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8831861</ArticleId><ArticleId IdType="pubmed">35155571</ArticleId></ArticleIdList></Reference><Reference><Citation>The prognostic utility of cytokines in hospitalized COVID-19 patients. Andrejkovits ÁV, Huțanu A, Susányi EJ, Negrea V, Văsieșiu AM. J Crit Care Med (Targu Mures) 2023;9:208–217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10644278</ArticleId><ArticleId IdType="pubmed">37969879</ArticleId></ArticleIdList></Reference><Reference><Citation>Epigenomics in COVID-19; the link between DNA methylation, histone modifications and SARS-CoV-2 infection. Shirvaliloo M. Epigenomics. 2021;13:745–750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8074570</ArticleId><ArticleId IdType="pubmed">33876664</ArticleId></ArticleIdList></Reference><Reference><Citation>Role of Epstein-Barr virus and human papillomavirus coinfection in cervical intraepithelial neoplasia in Chinese women living with HIV. Feng M, Duan R, Gao Y, Zhang H, Qiao Y, Li Q, Zhao F. Front Cell Infect Microbiol. 2021;11:703259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8453025</ArticleId><ArticleId IdType="pubmed">34557425</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood DNA methylation and COVID-19 outcomes. Balnis J, Madrid A, Hogan KJ, et al. Clin Epigenetics. 2021;13:118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8148415</ArticleId><ArticleId IdType="pubmed">34034806</ArticleId></ArticleIdList></Reference><Reference><Citation>Histone H3 cleavage in severe COVID-19 ICU patients. Huckriede J, de Vries F, Hultström M, et al. Front Cell Infect Microbiol. 2021;11:694186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8461091</ArticleId><ArticleId IdType="pubmed">34568088</ArticleId></ArticleIdList></Reference><Reference><Citation>Epigenetic perspectives associated with COVID-19 infection and related cytokine storm: an updated review. Dey A, Vaishak K, Deka D, et al. Infection. 2023;51:1603–1618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10008189</ArticleId><ArticleId IdType="pubmed">36906872</ArticleId></ArticleIdList></Reference><Reference><Citation>Elevated interleukin (IL)-6 as a predictor of disease severity among Covid-19 patients: a prospective cohort study. Nikkhoo B, Mohammadi M, Hasani S, et al. BMC Infect Dis. 2023;23:311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10169099</ArticleId><ArticleId IdType="pubmed">37161412</ArticleId></ArticleIdList></Reference><Reference><Citation>Histone mRNA polyadenylation-mediated inflammation underlies various virus infections and cancers. Guo M, Zhu J, Hu Z, Wang Q, Songyang Z, Xiong Y. J Med Virol. 2023;95:0.</Citation><ArticleIdList><ArticleId IdType="pubmed">37254821</ArticleId></ArticleIdList></Reference><Reference><Citation>Return of the coronavirus: 2019-nCoV. Gralinski LE, Menachery VD. Viruses. 2020;12:135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7077245</ArticleId><ArticleId IdType="pubmed">31991541</ArticleId></ArticleIdList></Reference><Reference><Citation>Accessory proteins of SARS-CoV and other coronaviruses. Liu DX, Fung TS, Chong KK, Shukla A, Hilgenfeld R. Antiviral Res. 2014;109:97–109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7113789</ArticleId><ArticleId IdType="pubmed">24995382</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus genomics and bioinformatics analysis. Woo PC, Huang Y, Lau SK, Yuen KY. Viruses. 2010;2:1804–1820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3185738</ArticleId><ArticleId IdType="pubmed">21994708</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Su S, Wong G, Shi W, et al. Trends Microbiol. 2016;24:490–502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7125511</ArticleId><ArticleId IdType="pubmed">27012512</ArticleId></ArticleIdList></Reference><Reference><Citation>Molecular evolution of human coronavirus genomes. Forni D, Cagliani R, Clerici M, Sironi M. Trends Microbiol. 2017;25:35–48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7111218</ArticleId><ArticleId IdType="pubmed">27743750</ArticleId></ArticleIdList></Reference><Reference><Citation>Human coronaviruses: what do they cause? van der Hoek L. https://pubmed.ncbi.nlm.nih.gov/17944272/ Antivir Ther. 2007;12:651–658.</Citation><ArticleIdList><ArticleId IdType="pubmed">17944272</ArticleId></ArticleIdList></Reference><Reference><Citation>Human coronaviruses: a review of virus-host interactions. Lim YX, Ng YL, Tam JP, Liu DX. Diseases. 2016;4:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5456285</ArticleId><ArticleId IdType="pubmed">28933406</ArticleId></ArticleIdList></Reference><Reference><Citation>Identification of a novel coronavirus in patients with severe acute respiratory syndrome. Drosten C, Günther S, Preiser W, et al. N Engl J Med. 2003;348:1967–1976.</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronaviruses: an overview of their replication and pathogenesis. Fehr AR, Perlman S. Methods Mol Biol. 2015;1282:1–23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4369385</ArticleId><ArticleId IdType="pubmed">25720466</ArticleId></ArticleIdList></Reference><Reference><Citation>The SARS-CoV S glycoprotein: expression and functional characterization. Xiao X, Chakraborti S, Dimitrov AS, Gramatikoff K, Dimitrov DS. Biochem Biophys Res Commun. 2003;312:1159–1164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7111010</ArticleId><ArticleId IdType="pubmed">14651994</ArticleId></ArticleIdList></Reference><Reference><Citation>Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. Matsuyama S, Nagata N, Shirato K, Kawase M, Takeda M, Taguchi F. J Virol. 2010;84:12658–12664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3004351</ArticleId><ArticleId IdType="pubmed">20926566</ArticleId></ArticleIdList></Reference><Reference><Citation>The molecular biology of coronaviruses. Masters PS. Adv Virus Res. 2006;66:193–292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112330</ArticleId><ArticleId IdType="pubmed">16877062</ArticleId></ArticleIdList></Reference><Reference><Citation>Insight into the recent 2019 novel coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaks. Ashour HM, Elkhatib WF, Rahman MM, Elshabrawy HA. Pathogens. 2020;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7157630</ArticleId><ArticleId IdType="pubmed">32143502</ArticleId></ArticleIdList></Reference><Reference><Citation>Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, Bates P. Proc Natl Acad Sci U S A. 2004;101:4240–4245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384725</ArticleId><ArticleId IdType="pubmed">15010527</ArticleId></ArticleIdList></Reference><Reference><Citation>The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. Antiviral Res. 2020;176:104742.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7114094</ArticleId><ArticleId IdType="pubmed">32057769</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 and cancer: insights into their association and influence on genetic and epigenetic landscape. Ghosh MK, Kumar S, Ganguly KK, Ghosh P, Tabassum S, Basu B, Basu M. Epigenomics. 2023;15:227–248.</Citation></Reference><Reference><Citation>Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. Wan Y, Shang J, Graham R, Baric RS, Li F. J Virol. 2020;94</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7081895</ArticleId><ArticleId IdType="pubmed">31996437</ArticleId></ArticleIdList></Reference><Reference><Citation>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Wrapp D, Wang N, Corbett KS, et al. Science. 2020;367:1260–1263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164637</ArticleId><ArticleId IdType="pubmed">32075877</ArticleId></ArticleIdList></Reference><Reference><Citation>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lu R, Zhao X, Li J, et al. Lancet. 2020;395:565–574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159086</ArticleId><ArticleId IdType="pubmed">32007145</ArticleId></ArticleIdList></Reference><Reference><Citation>Functional analysis of potential cleavage sites in the MERS-coronavirus spike protein. Kleine-Weber H, Elzayat MT, Hoffmann M, Pöhlmann S. Sci Rep. 2018;8:16597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6226446</ArticleId><ArticleId IdType="pubmed">30413791</ArticleId></ArticleIdList></Reference><Reference><Citation>Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Li W, Moore MJ, Vasilieva N, et al. Nature. 2003;426:450–454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095016</ArticleId><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference><Reference><Citation>ACE2 expression is increased in the lungs of patients with comorbidities associated with severe COVID-19. Pinto BG, Oliveira AE, Singh Y, et al. J Infect Dis. 2020;222:556–563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7377288</ArticleId><ArticleId IdType="pubmed">32526012</ArticleId></ArticleIdList></Reference><Reference><Citation>Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. Li W, Zhang C, Sui J, et al. EMBO J. 2005;24:1634–1643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1142572</ArticleId><ArticleId IdType="pubmed">15791205</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID- 19: a new virus, but a familiar receptor and cytokine release syndrome. Hirano T, Murakami M. Immunity. 2020;52:731–733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7175868</ArticleId><ArticleId IdType="pubmed">32325025</ArticleId></ArticleIdList></Reference><Reference><Citation>A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Kuba K, Imai Y, Rao S, et al. Nat Med. 2005;11:875–879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095783</ArticleId><ArticleId IdType="pubmed">16007097</ArticleId></ArticleIdList></Reference><Reference><Citation>Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV. Li R, Qiao S, Zhang G. J Infect. 2020;80:469–496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7127620</ArticleId><ArticleId IdType="pubmed">32092392</ArticleId></ArticleIdList></Reference><Reference><Citation>The role of type II transmembrane serine protease-mediated signaling in cancer. Tanabe LM, List K. FEBS J. 2017;284:1421–1436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5432387</ArticleId><ArticleId IdType="pubmed">27870503</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID‑19 and SARS‑CoV‑2 host cell entry mediators: expression profiling of TMRSS4 in health and disease. Katopodis P, Kerslake R, Davies J, et al. Int J Mol Med. 2021;47:64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7914073</ArticleId><ArticleId IdType="pubmed">33649798</ArticleId></ArticleIdList></Reference><Reference><Citation>Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Li MY, Li L, Zhang Y, Wang XS. Infect Dis Poverty. 2020;9:45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7186534</ArticleId><ArticleId IdType="pubmed">32345362</ArticleId></ArticleIdList></Reference><Reference><Citation>Urgent need for evaluating agonists of angiotensin-(1-7)/Mas receptor axis for treating patients with COVID-19. Shete A. Int J Infect Dis. 2020;96:348–351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7204665</ArticleId><ArticleId IdType="pubmed">32389847</ArticleId></ArticleIdList></Reference><Reference><Citation>TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Bestle D, Heindl MR, Limburg H, et al. Life Sci Alliance. 2020;3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383062</ArticleId><ArticleId IdType="pubmed">32703818</ArticleId></ArticleIdList></Reference><Reference><Citation>A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Hoffmann M, Kleine-Weber H, Pöhlmann S. Mol Cell. 2020;78:779–784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194065</ArticleId><ArticleId IdType="pubmed">32362314</ArticleId></ArticleIdList></Reference><Reference><Citation>Angiotensin-converting enzyme 2-angiotensin (1-7)-Mas axis prevents pancreatic acinar cell inflammatory response via inhibition of the p38 mitogen-activated protein kinase/nuclear factor-κB pathway. Yu X, Cui L, Hou F, et al. Int J Mol Med. 2018;41:409–420.</Citation><ArticleIdList><ArticleId IdType="pubmed">29138810</ArticleId></ArticleIdList></Reference><Reference><Citation>Association of angiotensin I converting enzyme insertion/deletion polymorphism with breast cancer: a meta-analysis. Sun M, Liu C, Wei F, Zhong J, Sun Y. J Renin Angiotensin Aldosterone Syst. 2011;12:611–616.</Citation><ArticleIdList><ArticleId IdType="pubmed">21546404</ArticleId></ArticleIdList></Reference><Reference><Citation>Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Millet JK, Whittaker GR. Proc Natl Acad Sci U S A. 2014;111:15214–15219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4210292</ArticleId><ArticleId IdType="pubmed">25288733</ArticleId></ArticleIdList></Reference><Reference><Citation>Expression of the renin-angiotensin system components in oncological diseases. Dolomatov S, Zukow W, Novikov N, Markaryan A, Eremeeva E. Acta Clin Croat. 2019;58:354–364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6884393</ArticleId><ArticleId IdType="pubmed">31819334</ArticleId></ArticleIdList></Reference><Reference><Citation>The effect of local renin angiotensin system in the common types of cancer. Almutlaq M, Alamro AA, Alamri HS, Alghamdi AA, Barhoumi T. Front Endocrinol (Lausanne) 2021;12:736361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8446618</ArticleId><ArticleId IdType="pubmed">34539580</ArticleId></ArticleIdList></Reference><Reference><Citation>The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer. Feng Y, Wan H, Liu J, et al. Oncol Rep. 2010;23:941–948.</Citation><ArticleIdList><ArticleId IdType="pubmed">20204277</ArticleId></ArticleIdList></Reference><Reference><Citation>The relationship between three well-characterized polymorphisms of the angiotensin converting enzyme gene and lung cancer risk: a case-control study and a meta-analysis. Gao M, Wang Y, Shi Y, et al. J Renin Angiotensin Aldosterone Syst. 2012;13:455–460.</Citation><ArticleIdList><ArticleId IdType="pubmed">22538550</ArticleId></ArticleIdList></Reference><Reference><Citation>Association of angiotensin converting enzyme gene insertion/deletion polymorphism with lung cancer in Turkey. Nacak M, Nacak I, Sanli M, Ozkur M, Pektaş M, Aynacioğlu AS. Cancer Genet Cytogenet. 2010;198:22–26.</Citation><ArticleIdList><ArticleId IdType="pubmed">20303010</ArticleId></ArticleIdList></Reference><Reference><Citation>Furin-mediated protein processing in infectious diseases and cancer. Braun E, Sauter D. Clin Transl Immunology. 2019;8:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6682551</ArticleId><ArticleId IdType="pubmed">31406574</ArticleId></ArticleIdList></Reference><Reference><Citation>The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer. He Z, Thorrez L, Siegfried G, et al. Oncogene. 2020;39:3571–3587.</Citation><ArticleIdList><ArticleId IdType="pubmed">32139876</ArticleId></ArticleIdList></Reference><Reference><Citation>The proprotein convertase furin in tumour progression. Jaaks P, Bernasconi M. Int J Cancer. 2017;141:654–663.</Citation><ArticleIdList><ArticleId IdType="pubmed">28369813</ArticleId></ArticleIdList></Reference><Reference><Citation>2019-nCoV-SARS-CoV-2 (COVID-19) infection: cruciality of Furin and relevance with cancer. Usul Afsar C. Med Hypotheses. 2020;140:109770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7195133</ArticleId><ArticleId IdType="pubmed">32344311</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 and corticosteroids: a narrative review. El-Saber Batiha G, Al-Gareeb AI, Saad HM, Al-Kuraishy HM. Inflammopharmacology. 2022;30:1189–1205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9106274</ArticleId><ArticleId IdType="pubmed">35562628</ArticleId></ArticleIdList></Reference><Reference><Citation>Corticosteroids in COVID-19: pros and cons. Bahsoun A, Fakih Y, Zareef R, Bitar F, Arabi M. Front Med (Lausanne) 2023;10:1202504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10461317</ArticleId><ArticleId IdType="pubmed">37644981</ArticleId></ArticleIdList></Reference><Reference><Citation>Co-infection of Epstein-Barr virus and human papillomavirus in human tumorigenesis. Shi Y, Peng SL, Yang LF, Chen X, Tao YG, Cao Y. Chin J Cancer. 2016;35:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4724123</ArticleId><ArticleId IdType="pubmed">26801987</ArticleId></ArticleIdList></Reference><Reference><Citation>Incidence of Epstein-Barr virus reactivation is elevated in COVID-19 patients. Bernal KD, Whitehurst CB. Virus Res. 2023;334:199157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10292739</ArticleId><ArticleId IdType="pubmed">37364815</ArticleId></ArticleIdList></Reference><Reference><Citation>The impact of the COVID-19 pandemic on the prevalence and genotype distribution of HPV infection in Beijing, China. Yi J, Li X, Zhang R, et al. J Med Virol. 2023;95:0.</Citation><ArticleIdList><ArticleId IdType="pubmed">37815056</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer as a prospective sequela of long COVID-19. Saini G, Aneja R. Bioessays. 2021;43:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8206711</ArticleId><ArticleId IdType="pubmed">33914346</ArticleId></ArticleIdList></Reference><Reference><Citation>Long-term effects of COVID-19 on cancer patients: the experience from Guy's Cancer Centre. Monroy-Iglesias MJ, Tremble K, Russell B, et al. Future Oncol. 2022;18:3585–3594.</Citation><ArticleIdList><ArticleId IdType="pubmed">36172860</ArticleId></ArticleIdList></Reference><Reference><Citation>Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. Pinato DJ, Tabernero J, Bower M, et al. Lancet Oncol. 2021;22:1669–1680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8565932</ArticleId><ArticleId IdType="pubmed">34741822</ArticleId></ArticleIdList></Reference><Reference><Citation>The COVID-19 pandemic impact on breast cancer diagnosis: a retrospective study. Negrao EM, Cabello C, Conz L, Mauad EC, Zeferino LC, Vale DB. Rev Bras Ginecol Obstet. 2022;44:871–877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9948273</ArticleId><ArticleId IdType="pubmed">35667376</ArticleId></ArticleIdList></Reference><Reference><Citation>High risk of heart tumors after COVID-19. Mitrofanova L, Makarov I, Goncharova E, Makarova T, Starshinova A, Kudlay D, Shlaykhto E. Life (Basel) 2023;13:2087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10608002</ArticleId><ArticleId IdType="pubmed">37895467</ArticleId></ArticleIdList></Reference><Reference><Citation>A rare adverse effects of COVID-19 vaccine in a patient with a latent tumor: a case report and literature review. Xu W, Nian W. Front Oncol. 2023;13:1269735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10728639</ArticleId><ArticleId IdType="pubmed">38115902</ArticleId></ArticleIdList></Reference><Reference><Citation>Expression of SARS-CoV-2-related surface proteins in non-small-cell lung cancer patients and the influence of standard of care therapy. Deben C, Le Compte M, Siozopoulou V, et al. Cancers (Basel) 2022;14:4074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9454734</ArticleId><ArticleId IdType="pubmed">36077610</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>